Early-stage equity raises for biotechs surged by 71% in Q3 2025, suggesting the funding freeze that has gripped the industry this year could be thawing. Total venture financing deal value in the biotech industry reached $3.1bn in Q3 this year, up from $1.8bn from the same period in 2024, as per a report by GlobalData. Marking a 70.9% jump between the two quarters, the increase signals renewed investor confidence in innovation and growth prospects, according to analysts from GlobalData. Despite a lacklust ...